## Leqembi



InfusionForHealth.com Ph: 888-777-1945 | Fax: 805-852-2636

Date: Trea	tment Location:
ments of cognitive function, brain imaging/test recent brain MRI establishing presence/lack of	ce visit note(s)/H&P substantiating diagnosis including assessing confirming presence of amyloid beta pathology (i.e., PET, LP), f pre-existing ARIA, and results of ApoE e4 genetic testing if done.  RIOR to administering the 5th, 7th, and 14th infusions.  Indicate the substantiating diagnosis including assessing the pathology (i.e., PET, LP), and pre-existing the substantiating diagnosis including assessing the pathology (i.e., PET, LP), and pre-existing if done.
PATIENT INFORMATION	PRESCRIBER INFORMATION
Patient Name:	Prescriber's Name:
Patient Contact Number:	Signature:
DOB:	NPI: Date:
Allergies:	Phone: Fax:
Weight: lbs / kg Height:	Office Address:
Diagnosis: ☐ G30 ☐ G30.0 ☐ G30.1 ☐ G30.9	Contact Person:
Other Dx/ICD10:	Contact Email:
Pre-Medications: No pre-medications inc	licated.
☐ Please prescribe and administer per Infusion for Health Provider discretion.	
LECANEMAB-IRMB (LEQEMBI) DOSAGE:	
Date of Last Treatment, If Continuation:	
Dose: □ 10 mg/kg □	Total Dose: Route: IV
Frequency: □ once every 2 weeks □ _	
Start Date of infusion:	
To ensure that a brand name product be dispe prescription form. If not indicated, Infus.	nsed, the prescriber must handwrite "Brand Medically Necessary" on ion for Health is authorized to administer generic or biosimilar.
Lab Orders:	Prior to first appointment Other Frequency:
☐ Please check this box if you <b>DO NOT</b> authorize clearance and/or insurance authorization prior to	Infusion for Health to order and draw labs indicated for clinical treatment.
· ·	Infusion for Health to complete a Peer to Peer on behalf of the

prescribing provider for an insurance company that denies authorization for treatment.